Biocytogen Pharmaceuticals (Beijing) Co., Ltd. today announced that the US FDA has approved the Investigational New Drug (IND) application for a phase I study of YH008, an internally developed first-in-class PD-1 x CD40 bispecific antibody. The IND application was completed by Biocytogen’s wholly owned subsidiary Eucure Biopharma. The trial is an open-label, dose-escalation study (No. YH008101) that will evaluate the safety, tolerability, pharmacokinetics and preliminary anti-

CenSyn, a digital telehealth company advancing portable screening of brain health-related conditions via its platform for integrated brain health screening, is pleased to announce its strategic partnership with HonorHealth, a leading healthcare system serving 1.6 million people in the greater Phoenix area. Rapid, out-of-hospital access to brain vitals is important to accelerate the diagnosis of brain health-related conditions where current traditional gold-standard equipment may be

As part of its commitment to connecting the Palm Beach County and Treasure Coast communities to world-class care, Tampa General Hospital is launching a concierge primary health care practice on Florida's East Coast. Dr. Laurie P. Rothman is the first doctor to join TGH Concierge Health. Rothman is a concierge primary care physician, board-certified in family medicine and in obesity medicine. She has two decades of experience delivering world-class care to patients in Palm Beach

The deployment of an artificial intelligence (AI) based image analysis software for the diagnosis of hip dysplasia can save time and costs without compromising the reliability of the diagnosis. This is the result of a recently published external validation study that tested IB Lab HIPPO - a musculoskeletal software tool by ImageBiopsy Lab, Austria (IB Lab). Currently the diagnosis of hip dysplasia, an abnormality of the hip joint, is based on time and cost consuming manual radiological measur

Virgin Pulse, the leading global digital-first health, wellbeing, and navigation company, today announced that it has entered into a collaborative agreement with Medsphere Systems Corporation, the leading provider of affordable and interoperable healthcare IT platform solutions and services. The two companies have established a long-term referral partnership that makes Medsphere's Marketware physician relationship management (PRM) platform the preferred solution for Virgin Pulse

Global Healthcare Accreditation is pleased to announce that BPK9 International Hospital in Bangkok, Thailand is awarded with GHA Accreditation for Medical Travel Services.BPK9 International Hospital is one of the leading private hospitals in Thailand, offering local and international patients access to an expert team of doctorss, the very latest medical equipment and the highest standards of medical care.GHA is recognized as a global accreditation leader for safety, health and well-being, hav

Carisk Partners an MBF Healthcare Partners II LP portfolio company providing specialty risk transfer and care coordination services in the workers’ compensation market, is pleased to announce the completion of its acquisition of Advanced Claims Review Specialists  a medical cost containment company utilizing evidence-based analysis of medical bills and records. The acquisition enhances Carisk’s ability to manage the costs of billed charges related to the clinical management o

Mawi DNA Technologies a medical device company focused on developing innovative technologies for biosampling, announced today that the company has signed a Memorandum of Understanding  with Morocco's Ministry of Investments , Convergence and Public Policy Evaluation and signed with the Moroccan Ministry of Industry and Commerce (MIC) to establish a joint venture with Mawi's regional partner BIOTESSIAto set up a state-of-the-art production facility in Morocco to serve the African

Medivir AB, a pharmaceutical company focused on developing innovative treatments for cancer in areas of high unmet medical need, announced today that the company has completed a pre-IND meeting with the US Food and Drug Administration and has received positive feedback on the development plan in preparation for an IND for its candidate drug fostroxacitabine bralpamide (fostrox). This is a significant step towards an application to include American study centers in future clinical trials (Inve

IRRAS, a commercial-stage medical technology company with a comprehensive portfolio of innovative products for neurocritical care, today announced that it received regulatory clearance from the United States Food, Drug, and Administration (FDA) to active all of the functionality on the next generation control unit for its flagship product, IRRAflow, the world's first and only active fluid exchange system. Earlier this year, IRRAS introduced this next-generation IRRAflow system,